Treatment of Recurrent Osteosarcoma and UPS of Bone

Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 2, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Approximately 50% of relapses in patients with recurrent osteosarcoma occur within 18 months of therapy termination, and only 5% of recurrences develop beyond 5 years.[1-4]

Source links and citations

Continue within this section

Prognostic Factors for Recurrence →Treatment Options for Recurrent Osteosarcoma and UPS of Bone →Treatment Options for Local Recurrence →Treatment Options for Lung-Only Recurrence →Treatment Options for Recurrence With Bone-Only Metastases →Treatment Options for Second Recurrence of Osteosarcoma →Treatment Options Under Clinical Evaluation →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice